APA (7th ed.) Citation

M, W., TAW, H., JJ, L., VK, M., WH, A., K, W., . . . CM, B. (2024). First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. Journal for immunotherapy of cancer, 12(7), . https://doi.org/10.1136/jitc-2023-008668

Chicago Style (17th ed.) Citation

M, Wermke, et al. "First-in-human Dose Escalation Trial to Evaluate the Clinical Safety and Efficacy of an Anti-MAGEA1 Autologous TCR-transgenic T Cell Therapy in Relapsed and Refractory Solid Tumors." Journal for Immunotherapy of Cancer 12, no. 7 (2024). https://doi.org/10.1136/jitc-2023-008668.

MLA (9th ed.) Citation

M, Wermke, et al. "First-in-human Dose Escalation Trial to Evaluate the Clinical Safety and Efficacy of an Anti-MAGEA1 Autologous TCR-transgenic T Cell Therapy in Relapsed and Refractory Solid Tumors." Journal for Immunotherapy of Cancer, vol. 12, no. 7, 2024, https://doi.org/10.1136/jitc-2023-008668.